Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

3351 results

Sort By:

An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors

Study ID: NCT06667726
Start Date: 2026-05-01
End Date: 2029-10-08
Study Type

Interventional

Study Phase

Phase2

No. of Participants

47

Intervention / Treatment

Computed Tomography

Fluorodopa F 18

Positron Emission Tomography

Sponsor

Mayo Clinic

Source: clinicaltrials.gov

Share:
Add to list

Comparison of Dressing Materials of Donor Site of Split-thickness Skin Graft; Paraffin Mesh Gauze vs Povidone-Iodine Foam at SMBB Institute of Trauma Karachi

Study ID: NCT07257991
Start Date: 2026-01-01
End Date: 2026-05-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

82

Intervention / Treatment

Povidine-iodine foam dressing for donor site of Split-thickness skin graft

Paraffin mesh gauze dressing for donor site of Split-thickness skin graft

Sponsor

Shaheed Mohtarma Benazir Bhutto Institute of Trauma

Source: clinicaltrials.gov

Share:
Add to list

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment

Study ID: NCT07275216
Start Date: 2026-07-01
End Date: 2027-11-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

23

Intervention / Treatment

Biospecimen Collection

Brentuximab Vedotin

Computed Tomography

Dacarbazine

Echocardiography Test

Gemcitabine

Pembrolizumab

Physical Performance Testing

Positron Emission Tomography

Pulmonary Function Test

Sponsor

City of Hope Medical Center

Source: clinicaltrials.gov

Share:
Add to list

Study of JTM104 Injection vs. Juvederm in Treating Moderate to Severe Nasolabial Folds

Study ID: NCT07265791
Start Date: 2026-01-03
End Date: 2027-01-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment

JTM104

Juvederm® ULTRA PLUS XC

Sponsor

Jetema Co., Ltd.

Source: clinicaltrials.gov

Share:
Add to list

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Study ID: NCT04563520
Start Date: 2026-01
End Date: 2027-01
Study Type

Interventional

Study Phase

Phase3

No. of Participants

5

Intervention / Treatment

emicizumab

Favor

rFVIIa

Sponsor

Emory University

Source: clinicaltrials.gov

Share:
Add to list

Implications of Circadian Variation of Human Endocannabinoid Levels on Obesity Risk

Study ID: NCT03000803
Start Date: 2026-10
End Date: 2029-10
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment

Early Total Caloric Intake

Late Total Caloric Intake

Sponsor

University of Chicago

Source: clinicaltrials.gov

Share:
Add to list

Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct

Study ID: NCT05054790
Start Date: 2026-06
End Date: 2027-06
Study Type

Interventional

Study Phase

Phase2

No. of Participants

10

Intervention / Treatment

"Neo-Bladder" Construct

Sponsor

Wake Forest University Health Sciences

Source: clinicaltrials.gov

Share:
Add to list

Effects of Virtual Reality and Stress Ball on Fear, Pain, Anxiety, and Satisfaction in Ureterorenoscopy Patients

Study ID: NCT07265960
Start Date: 2025-12-15
End Date: 2026-12-15
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

90

Intervention / Treatment

Virtual Reality

Stress Ball

Sponsor

Tarsus University

Source: clinicaltrials.gov

Share:
Add to list

Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors

Study ID: NCT06139783
Start Date: 2026-05
End Date: 2027-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

32

Intervention / Treatment

Exercise and dietary recommendations

Sponsor

Oncare Madrid

Source: clinicaltrials.gov

Share:
Add to list

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

Study ID: NCT06041503
Start Date: 2025-12-18
End Date: 2028-10-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

68

Intervention / Treatment

Pembrolizumab

Enfortumab vedotin

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list